🟢 Edesa Biotech is trading 14.54% up in after-hours trading with no identified company-specific explanation

Edesa Biotech is trading at $3.23, up 14.54%, with no identified company-specific announcement explaining the October 20 after-hours move.

• Its latest located catalyst was FDA clearance announced October 15 to expand the Phase 2 EB06 vitiligo study into the United States.
• The trial’s first U.S. sites are expected to begin enrolling next quarter, with topline data anticipated in Q4 2027.
• Market context shows modest index gains but does not establish a direct connection to the move.